{"generic":"Daclatasvir","drugs":["Daclatasvir"],"mono":{"0":{"id":"jyems0","title":"Generic Names","mono":"Daclatasvir"},"1":{"id":"jyems1","title":"Dosing and Indications","sub":[{"id":"jyems1b4","title":"Adult Dosing","mono":"<ul><li>usual dose 60 mg once daily<\/li><li>safety and efficacy have not been established in patients with decompensated liver disease; pre-, peri-, or post-liver or other organ transplantation; or coinfection with HIV or hepatitis B virus<\/li><li><b>Hepatitis C, chronic, Genotype 1 with compensated cirrhosis, in combination with sofosbuvir:<\/b> 60 mg ORALLY once daily in combination with sofosbuvir for 24 weeks; may reduce treatment to 12 weeks in treatment-naive patients with positive prognostic factors (ie, IL28B CC genotype and\/or low baseline viral load); for patients with advanced disease or other negative prognostic factors (ie, previous treatment exposure) consider adding ribavirin (1000 mg for body weight less than 75 kg; 1200 mg for weight 75 kg or more) (European Medicines Agency-approved dosing)<\/li><li><b>Hepatitis C, chronic, Genotype 1 without cirrhosis, in combination with sofosbuvir:<\/b> 60 mg ORALLY once daily in combination with sofosbuvir for 12 weeks; may consider extending treatment to 24 weeks in patients who have received prior treatment with NS3\/4A protease inhibitor  (European Medicines Agency-approved dosing)<\/li><li><b>Hepatitis C, chronic, Genotype 3 with compensated cirrhosis and\/or treatment experienced, as a component of a combination antiviral treatment regimen:<\/b> 60 mg ORALLY once daily in combination with sofosbuvir and ribavirin (1000 mg for body weight less than 75 kg; 1200 mg for weight 75 kg or more) for 24 weeks<\/li><li><b>Hepatitis C, chronic, Genotype 4, in combination with peginterferon alfa and ribavirin:<\/b> 60 mg ORALLY once daily for 24 weeks in combination with peginterferon alfa and ribavirin (1000 mg for body weight less than 75 kg; 1200 mg for weight 75 kg or more) for 24 to 48 weeks (European Medicines Agency-approved dosing).<\/li><li><b>Hepatitis C, chronic, Genotype 4 with compensated cirrhosis, in combination with sofosbuvir:<\/b> 60 mg ORALLY once daily in combination with sofosbuvir for 24 weeks; may reduce duration to 12 weeks in treatment-naive patients with positive prognostic factors (ie, IL28B CC genotype and\/or low baseline viral load); for patients with advanced disease or other negative prognostic factors (ie, previous treatment exposure) consider adding ribavirin (1000 mg for body weight less than 75 kg; 1200 mg for weight 75 kg or more) (European Medicines Agency-approved dosing)<\/li><li><b>Hepatitis C, chronic, Genotype 4 without cirrhosis, in combination with sofosbuvir:<\/b> 60 mg ORALLY once daily in combination with sofosbuvir for 12 weeks; may consider extending treatment to 24 weeks in patients who have received prior treatment with NS3\/4A protease inhibitor  (European Medicines Agency-approved dosing)<\/li><\/ul>"},{"id":"jyems1b5","title":"Pediatric Dosing","mono":"safety and efficacy have not been established in pediatric patients "},{"id":"jyems1b6","title":"Dose Adjustments","mono":"<ul><li>dose reduction to manage adverse reactions is not recommended<\/li><li><b>renal impairment:<\/b> No adjustment is necessary<\/li><li><b>hepatic impairment:<\/b> No adjustment is necessary<\/li><li><b>geriatric:<\/b> No adjustment is necessary .<\/li><li>discontinue combination therapy of daclatasvir plus peginterferon alfa and ribavirin if the HCV RNA threshold at treatment week 4 exceeds 1000 international units\/mL or is 25 international units\/mL or greater at weeks 12 or 24; discontinuation parameters do apply when daclatasvir is used in combination with sofosbuvir<\/li><li>in combination with strong inhibitors of CYP3A4, reduce daclatasvir to 30 mg once daily<\/li><li>in combination with moderate inducers of CYP3A4, increase daclatasvir to 90 mg once daily<\/li><\/ul>"},{"id":"jyems1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><ul><li>Hepatitis C, chronic, Genotype 1 with compensated cirrhosis, in combination with sofosbuvir<\/li><li>Hepatitis C, chronic, Genotype 1 without cirrhosis, in combination with sofosbuvir<\/li><li>Hepatitis C, chronic, Genotype 3 with compensated cirrhosis and\/or treatment experienced, as a component of a combination antiviral treatment regimen<\/li><li>Hepatitis C, chronic, Genotype 4, in combination with peginterferon alfa and ribavirin<\/li><li>Hepatitis C, chronic, Genotype 4 with compensated cirrhosis, in combination with sofosbuvir<\/li><li>Hepatitis C, chronic, Genotype 4 without cirrhosis, in combination with sofosbuvir<\/li><\/ul>"}]},"3":{"id":"jyems3","title":"Contraindications\/Warnings","sub":[{"id":"jyems3b9","title":"Contraindications","mono":"<ul><li>concomitant use with strong CYP3A4 and P-gp inducers (eg, carbamazepine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifampicin, rifapentine, systemic dexamethasone, St John's wort)<\/li><li>hypersensitivity to daclatasvir or other components of the product<\/li><\/ul>"},{"id":"jyems3b10","title":"Precautions","mono":"<ul><li>Reproductive:<\/li><li>-- use is not recommended during pregnancy or in women of childbearing potential not using contraception; patient should use highly-effective contraception during therapy and for 5 weeks following completion<\/li><li>Other:<\/li><li>-- product contains lactose; use is not recommended in galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption<\/li><li>Concomitant Use:<\/li><li>-- use with darunavir, etravirine, lopinavir, and nevirapine not recommended<\/li><\/ul>"},{"id":"jyems3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jyems3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jyems4","title":"Drug Interactions","sub":[{"id":"jyems4b13","title":"Contraindicated","mono":"<ul><li>Carbamazepine (theoretical)<\/li><li>Dexamethasone (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Oxcarbazepine (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><\/ul>"},{"id":"jyems4b14","title":"Major","mono":"<ul><li>Apixaban (theoretical)<\/li><li>Aprepitant (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Atorvastatin (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Bosentan (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Delavirdine (theoretical)<\/li><li>Digoxin (theoretical)<\/li><li>Efavirenz (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Eslicarbazepine Acetate (theoretical)<\/li><li>Etravirine (theoretical)<\/li><li>Fluvastatin (theoretical)<\/li><li>Fosaprepitant (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Imatinib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Modafinil (theoretical)<\/li><li>Nafcillin (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Nevirapine (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pitavastatin (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Pravastatin (theoretical)<\/li><li>Prednisolone (theoretical)<\/li><li>Prednisone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Rosuvastatin (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Simeprevir (theoretical)<\/li><li>Simvastatin (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}]},"5":{"id":"jyems5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Gastrointestinal:<\/b>Nausea (10% or greater)<\/li><li><b>Neurologic:<\/b>Headache (10% or greater)<\/li><li><b>Other:<\/b>Fatigue (10% or greater)<\/li><\/ul><b>Serious<\/b><br\/><b>Hematologic:<\/b>Anemia, Grade 3 or higher (1% or greater), Lymphocytopenia, Grade 3 or higher (1% or greater), Neutropenia, Grade 3 or higher (1% or greater)<br\/>"},"6":{"id":"jyems6","title":"Drug Name Info","sub":{"3":{"id":"jyems6b20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"jyems7","title":"Mechanism Of Action","mono":"Daclatasvir is a nonstructural protein 5A (NS5A) inhibitor that interferes with the hepatitis C virus replication complex via inhibition of viral RNA replication and virion assembly. Daclatasvir is highly selective for HCV.<br\/>"},"8":{"id":"jyems8","title":"Pharmacokinetics","sub":[{"id":"jyems8b23","title":"Absorption","mono":"<ul><li>Tmax, oral: 1 to 2 hours<\/li><li>Bioavailability, oral: 67%<\/li><li>Effects of food: High fat meal, decrease Cmax 28%, decrease AUC 23%; light meal, no effect on exposure<\/li><\/ul>"},{"id":"jyems8b24","title":"Distribution","mono":"<ul><li>Protein binding: 99%<\/li><li>Vd: 47 L<\/li><\/ul>"},{"id":"jyems8b25","title":"Metabolism","mono":"<ul><li>Liver: primary site via CYP3A4<\/li><li>inhibitor of P-glycoprotein (P-gp), OATP 1B1, and BCRP<\/li><li>substrate of CYP3A4 and P-gp<\/li><\/ul>"},{"id":"jyems8b26","title":"Excretion","mono":"<ul><li>Fecal: 88% total, 53% unchanged<\/li><li>Renal: 6.6% primarily unchanged<\/li><li>Dialyzable: No (hemodialysis)<\/li><li>Total body clearance: 4.24 L\/hr<\/li><\/ul>"},{"id":"jyems8b27","title":"Elimination Half Life","mono":"12 to 15 hours <br\/>"}]},"9":{"id":"jyems9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>monotherapy not recommended; always administer in combination with sofosbuvir and\/or ribavirin or peginterferon alfa and\/or ribavirin<br\/><\/li><li><b>Oral<\/b><br\/>may take with or without food<br\/><\/li><\/ul>"},"10":{"id":"jyems10","title":"Monitoring","mono":"<ul><li>hepatitis C genotype: prior to initiation of therapy<\/li><li>hepatitis C RNA load: during therapy<\/li><\/ul>"},"13":{"id":"jyems13","title":"Clinical Teaching","mono":"<ul><li>Recommend female patient avoid pregnancy during therapy and for 5 weeks post-treatment.<\/li><li>Side effects may include fatigue, nausea, diarrhea, constipation, vomiting, depression, anxiety, insomnia, dizziness, dyspnea, pruritus, alopecia, rash, arthralgia, or myalgia.<\/li><li>Instruct  patient to take a missed dose as soon as possible, but if next dose is in less than 4 hours, skip the missed dose.<\/li><\/ul>"}}}